LUT-014 is under clinical development by Lutris Pharma and currently in Phase II for Acne And Related Disorders. According to GlobalData, Phase II drugs for Acne And Related Disorders have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LUT-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LUT-014 is under development for the treatment of EGFR inhibitor induced acneiform lesions in adult metastatic colorectal cancer patients and radiation induced dermatitis in breast cancer patients. The drug candidate is administered through topical route. The drug candidate act by targeting BRAF.
Lutris Pharma overview
Lutris Pharma is a company that creates therapeutic medications to help with cancer treatment. The company’s drug is known as the B-Raf inhibitor LUT014, a proprietary small molecule that allows medical professionals to administer epidermal growth factor receptor (EGFR) inhibitors to patients without the interruptions caused by typical cutaneous side effects, allowing them to improve anti-cancer therapy effectiveness as well as patient quality of life. The company is headquartered in Israel.
For a complete picture of LUT-014’s drug-specific PTSR and LoA scores, buy the report here.